A $5.7 billion global medical bill to restore sight for the estimated 45 million people with cataracts could be slashed in half by a diet rich in colourful fruits and vegetables, according to an international study.
This study looked at the association of calcium intake (dietary and supplementation) with the risk and progression of age-related macular degeneration (AMD), a leading cause of blindness. Previous research has had mixed results about the role of calcium in AMD progression. This study, a secondary analysis of 4,751 randomized clinical trial participants, found higher calcium intake was associated with lower risk of progression to late AMD but there was an inconsistent association between calcium intake and different stages of AMD.
Eating a calcium-rich diet or taking calcium supplements does not appear to increase the risk of age-related macular degeneration (AMD), according to the findings of a study by scientists at the National Eye Institute (NEI). AMD is a leading cause of vision loss and blindness among people age 65 and older in the United States. The study findings are published in JAMA Ophthalmology.
Cells of the retinal pigment epithelium (RPE) form unique patterns that can be used to track changes in this important layer of tissue in the back of the eye, researchers at the National Eye Institute (NEI) have found. Using a combination of adaptive optics imaging and a fluorescent dye, the researchers used the RPE patterns to track individual cells in healthy volunteers and people with retinal disease.
An adhesive gel packed with light-activated chemicals can seal cuts or ulcers on the cornea -- the clear surface of the eye -- and then encourage the regeneration of corneal tissue, according to a preclinical study published online today in Science Advances. The new technology, named GelCORE (gel for corneal regeneration), could one day reduce the need for surgery to repair injuries to the cornea, including those that would today require corneal transplantation.
The ability of the brain to ignore extraneous visual information is critical to how we work and function, but the processes governing perception and attention are not fully understood. Scientists have long theorized that attention to a particular object can alter perception by amplifying certain neuronal activity and suppressing the activity of other neurons (brain 'noise'). Now, Salk scientists have confirmed this theory by showing how too much background noise from neurons can interrupt focused attention and cause the brain to struggle to perceive objects.
Low levels of amyloid-β and tau proteins, biomarkers of Alzheimer's disease (AD), in eye fluid were significantly associated with low cognitive scores, according to a new study. These findings indicate that proteins in the eye may be a potential source for an accessible, cost-effective test to predict future Alzheimer's disease.
As artificial intelligence continues to evolve, diagnosing disease faster and potentially with greater accuracy than physicians, some have suggested that technology may soon replace tasks that physicians currently perform.
People left blind by retinal degeneration have one option: electronic eye implants. UC Berkeley neuroscientists have developed an alternative: gene therapy that, in tests, restored vision in blind mice. A gene for green opsin delivered via virus gave blind mice enough sight to discern patterns on an iPad at a resolution sufficient for humans to read. Given existing AAV eye therapies already approved, this new therapy could be ready for clinical trials in three years.
Ganglion cells in the eye generate noise as the light-sensitive photoreceptors die in diseases such as retinitis pigmentosa. Now, UC Berkeley neurobiologists have found a drug and gene therapy that can tamp down the noise, improving sight in mice with RP. These therapies could potentially extend the period of useful vision in those with degenerative eye diseases, including, perhaps, age-related macular degeneration.